Information

You are on the new improved site. You can view the old site in view-only mode here until June 27, 2026

loading
FDA Orders New Phase III Trial for Anticancer Drug;SuperGen Withdraws Orathecin NDA;FDA Okays Keratinocyte Growth Factor for Prevention of Mucositis During Chemotherapy;AstraZeneca Withdraws Application for European Approval of Iressa;FDA Approves Anti-Angiogenesis Agent for "Wet" Age-Related Macular Degeneration;Access Pharmaceuticals Gets Clearance for Clinical Trials of AP5346;FDA Establishes Nanotechnology Site;Microarray Chip for Genetic Analysis Receives FDA Clearance